TY - JOUR
T1 - Pathogenesis of endometriosis
T2 - Interaction between Endocrine and inflammatory pathways
AU - Patel, Bansari G.
AU - Lenk, Emily E.
AU - Lebovic, Dan I.
AU - Shu, Yimin
AU - Yu, Jie
AU - Taylor, Robert N.
N1 - Publisher Copyright:
© 2018
PY - 2018/7
Y1 - 2018/7
N2 - Despite an estimated prevalence of 11% in women and plausible historical descriptions dating back to the 17th century, the etiology of endometriosis remains poorly understood. Classical theories of the histological origins of endometriosis are reviewed below. Clinical presentations are variable, and signs and symptoms do not correlate well with the extent of disease. In this summary, we have attempted to synthesize the growing evidence that hormonal and immune factors conspire to activate a local inflammatory microenvironment that encourages endometriosis to persist and elaborate mediators of its two cardinal symptoms: pain and infertility. Surprisingly, in the search for novel therapeutics for medical treatment of endometriosis, some compounds appear to have dual pharmacological functions, simultaneously modifying the endocrine and immune system facets of this complex gynecologic syndrome. We predict that these lead drugs will provide more therapeutic choices for patients in the future.
AB - Despite an estimated prevalence of 11% in women and plausible historical descriptions dating back to the 17th century, the etiology of endometriosis remains poorly understood. Classical theories of the histological origins of endometriosis are reviewed below. Clinical presentations are variable, and signs and symptoms do not correlate well with the extent of disease. In this summary, we have attempted to synthesize the growing evidence that hormonal and immune factors conspire to activate a local inflammatory microenvironment that encourages endometriosis to persist and elaborate mediators of its two cardinal symptoms: pain and infertility. Surprisingly, in the search for novel therapeutics for medical treatment of endometriosis, some compounds appear to have dual pharmacological functions, simultaneously modifying the endocrine and immune system facets of this complex gynecologic syndrome. We predict that these lead drugs will provide more therapeutic choices for patients in the future.
KW - Endometriosis
KW - Estrogen
KW - GnRH (gonadotropin-releasing hormone)
KW - Progesterone
KW - SERM (selective estrogen receptor modulator)
UR - http://www.scopus.com/inward/record.url?scp=85044309541&partnerID=8YFLogxK
U2 - 10.1016/j.bpobgyn.2018.01.006
DO - 10.1016/j.bpobgyn.2018.01.006
M3 - Review article
C2 - 29576469
AN - SCOPUS:85044309541
SN - 1521-6934
VL - 50
SP - 50
EP - 60
JO - Best Practice and Research: Clinical Obstetrics and Gynaecology
JF - Best Practice and Research: Clinical Obstetrics and Gynaecology
ER -